Inhibrx (INBX) Projected to Post Earnings on Thursday

Inhibrx (NASDAQ:INBX) is expected to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.

Inhibrx Trading Down 0.5 %

Shares of INBX stock opened at $12.52 on Wednesday. Inhibrx has a fifty-two week low of $10.80 and a fifty-two week high of $18.95. The stock has a 50 day moving average price of $14.19 and a two-hundred day moving average price of $14.61.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Insider Activity

In other Inhibrx news, Director Jon Faiz Kayyem purchased 69,686 shares of Inhibrx stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $14.23 per share, for a total transaction of $991,631.78. Following the acquisition, the director now directly owns 51,093 shares in the company, valued at approximately $727,053.39. This trade represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 22.20% of the company’s stock.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.